NDC product
Zolpidem Tartrate
NDC 13668-775 · TORRENT PHARMACEUTICALS LIMITED
Key facts
| Product NDC | 13668-775 |
|---|---|
| Proprietary name | Zolpidem Tartrate |
| Nonproprietary name | Zolpidem Tartrate |
| Substances | ZOLPIDEM TARTRATE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | TORRENT PHARMACEUTICALS LIMITED |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA220717 |
| DEA schedule | CIV |
| Pharmacologic classes | Central Nervous System Depression [PE], GABA A Receptor Positive Modulators [MoA], gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] |
| Marketing start | Jun 23, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: